Loading clinical trials...
Loading clinical trials...
Specified Drug-Use Survey on Entyvio for IV Infusion 300 mg [Crohn's Disease]
The purpose of this survey is to evaluate the long-term safety and effectiveness of vedolizumab for intravenous (IV) infusion 300 milligrams (mg) in Crohn's disease (CD) patients in the routine clinical setting.
The drug being tested in this survey is called vedolizumab for IV infusion 300 mg. This drug is being tested to treat patients who have CD. This survey is an observational (non-interventional) study and will look at the long-term safety and effectiveness of vedolizumab for IV infusion 300 mg in the routine clinical setting. The planned number of observed patients will be approximately 300. This multi-center observational trial will be conducted in Japan.
Age
All ages
Sex
ALL
Healthy Volunteers
No
Takeda Selected Site
Tokyo, Japan
Start Date
July 1, 2019
Primary Completion Date
June 30, 2026
Completion Date
June 30, 2026
Last Updated
January 7, 2026
335
ACTUAL participants
Vedolizumab (Genetical Recombination)
DRUG
Lead Sponsor
Takeda
NCT06226883
NCT07184931
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06918808